| Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas Q Deng, G Han, N Puebla-Osorio, MCJ Ma, P Strati, B Chasen, E Dai, ... Nature medicine 26 (12), 1878-1887, 2020 | 410 | 2020 |
| Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma P Mondello, S Tadros, M Teater, L Fontan, AY Chang, N Jain, H Yang, ... Cancer Discovery 10 (3), 440-459, 2020 | 124 | 2020 |
| Ruscogenin reduces cerebral ischemic injury via NF-κB-mediated inflammatory pathway in the mouse model of experimental stroke T Guan, Q Liu, Y Qian, H Yang, J Kong, J Kou, B Yu European journal of pharmacology 714 (1-3), 303-311, 2013 | 100 | 2013 |
| A combination of four active compounds alleviates cerebral ischemia–reperfusion injury in correlation with inhibition of autophagy and modulation of AMPK/mTOR and JNK pathways Z Guo, G Cao, H Yang, H Zhou, L Li, Z Cao, B Yu, J Kou Journal of neuroscience research 92 (10), 1295-1306, 2014 | 89 | 2014 |
| Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma MCJ Ma, S Tadros, A Bouska, T Heavican, H Yang, Q Deng, D Moore, ... Haematologica 107 (3), 690, 2022 | 59 | 2022 |
| Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression G Han, Q Deng, ML Marques-Piubelli, E Dai, M Dang, MCJ Ma, X Li, ... Blood cancer discovery 3 (5), 428-443, 2022 | 51 | 2022 |
| Rewiring cancer drivers to activate apoptosis S Gourisankar, A Krokhotin, W Ji, X Liu, CY Chang, SH Kim, Z Li, ... Nature 620 (7973), 417-425, 2023 | 46 | 2023 |
| Epigenetic programing of B-cell lymphoma by BCL6 and its genetic deregulation H Yang, MR Green Frontiers in cell and developmental biology, 272, 2019 | 44 | 2019 |
| Shengmai injection attenuates the cerebral ischemia/reperfusion induced autophagy via modulation of the AMPK, mTOR and JNK pathways H Yang, L Li, K Zhou, Y Wang, T Guan, C Chai, J Kou, B Yu, Y Yan Pharmaceutical biology 54 (10), 2288-2297, 2016 | 40 | 2016 |
| Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma HJJ Cherng, R Sun, B Sugg, R Irwin, H Yang, CC Le, Q Deng, L Fayad, ... Blood, The Journal of the American Society of Hematology 140 (5), 504-515, 2022 | 35 | 2022 |
| Diosgenin inhibits tumor necrosis factor-induced tissue factor activity and expression in THP-1 cells via down-regulation of the NF-κB, Akt, and MAPK signaling pathways Y Hao-Peng, YUE Lei, WW Jiang, LIU Qian, KOU Jun-Ping, YU Bo-Yang Chinese journal of natural medicines 11 (6), 608-615, 2013 | 29 | 2013 |
| BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma W Fiskus, CP Mill, D Perera, C Birdwell, Q Deng, H Yang, BH Lara, N Jain, ... Leukemia 35 (9), 2621-2634, 2021 | 20 | 2021 |
| Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells P Strati, X Li, Q Deng, ML Marques-Piubelli, J Henderson, G Watson, ... Cell Reports Medicine 4 (8), 2023 | 15 | 2023 |
| High-Efficiency “–1” and “–2” Ribosomal Frameshiftings Revealed by Force Spectroscopy TW Tsai, H Yang, H Yin, S Xu, Y Wang ACS chemical biology 12 (6), 1629-1635, 2017 | 15 | 2017 |
| Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discov. 2020; 10: 440–459. doi: 10.1158/2159-8290 P Mondello, S Tadros, M Teater, L Fontan, AY Chang, N Jain, H Yang, ... CD-19-0116, 0 | 13 | |
| Quantitatively resolving multivalent interactions on a macroscopic scale using force spectroscopy Q Hu, H Yang, Y Wang, S Xu Chemical Communications 52 (18), 3705-3708, 2016 | 11 | 2016 |
| Harnessing lymphoma epigenetics to improve therapies H Yang, MR Green Blood, The Journal of the American Society of Hematology 136 (21), 2386-2391, 2020 | 10 | 2020 |
| Pathognomonic and epistatic genetic alterations in B-cell non-Hodgkin lymphoma MCJ Ma, S Tadros, A Bouska, TB Heavican, H Yang, Q Deng, D Moore, ... bioRxiv, 674259, 2019 | 7 | 2019 |
| SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions Q Deng, P Lakra, P Gou, H Yang, C Meydan, M Teater, C Chin, W Zhang, ... Cancer cell 42 (4), 605-622. e11, 2024 | 5 | 2024 |
| Exchange-induced remnant magnetization for label-free detection of dna, micro-rna, and dna/rna-binding biomarkers S Xu, L Yao, Y Wang, HU Qiongzheng, Y Haopeng US Patent App. 14/247,953, 2014 | 5 | 2014 |
